Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer.

Ciucci A, Zannoni GF, Travaglia D, Petrillo M, Scambia G, Gallo D.

Gynecol Oncol. 2014 Feb;132(2):351-9. doi: 10.1016/j.ygyno.2013.12.027. Epub 2013 Dec 27.

PMID:
24378878
2.

Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer.

De Stefano I, Zannoni GF, Prisco MG, Fagotti A, Tortorella L, Vizzielli G, Mencaglia L, Scambia G, Gallo D.

Gynecol Oncol. 2011 Sep;122(3):573-9. doi: 10.1016/j.ygyno.2011.05.025. Epub 2011 Jun 12.

PMID:
21665249
3.

Hormone receptor expression profile of low-grade serous ovarian cancers.

Buttarelli M, Mascilini F, Zannoni GF, Ciucci A, Martinelli E, Filippetti F, Scambia G, Ferrandina G, Gallo D.

Gynecol Oncol. 2017 May;145(2):352-360. doi: 10.1016/j.ygyno.2017.02.029. Epub 2017 Feb 20.

PMID:
28228232
4.

Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.

Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V.

Clin Cancer Res. 2008 Aug 15;14(16):5228-35. doi: 10.1158/1078-0432.CCR-07-4528.

5.

Mitochondrial estrogen receptor β2 drives antiapoptotic pathways in advanced serous ovarian cancer.

Ciucci A, Zannoni GF, Travaglia D, Scambia G, Gallo D.

Hum Pathol. 2015 Aug;46(8):1138-46. doi: 10.1016/j.humpath.2015.03.016. Epub 2015 Apr 15.

PMID:
26003478
6.

Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.

Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H, Yaegashi N.

Cancer Sci. 2008 Dec;99(12):2365-72. doi: 10.1111/j.1349-7006.2008.00988.x. Epub 2008 Nov 17.

7.

Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion.

Leung YK, Lam HM, Wu S, Song D, Levin L, Cheng L, Wu CL, Ho SM.

Endocr Relat Cancer. 2010 Jun 25;17(3):675-89. doi: 10.1677/ERC-09-0294. Print 2010 Sep.

8.

Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers.

Yan M, Rayoo M, Takano EA; kConFab Investigators, Fox SB.

Breast Cancer Res Treat. 2011 Apr;126(2):395-405. doi: 10.1007/s10549-010-0941-9. Epub 2010 May 20.

PMID:
20490651
9.

Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer.

Davies MP, O'Neill PA, Innes H, Sibson DR, Prime W, Holcombe C, Foster CS.

J Mol Endocrinol. 2004 Dec;33(3):773-82.

PMID:
15591034
10.

Different associations of estrogen receptor β isoforms, ERβ1 and ERβ2, expression levels with tumor size and survival in early- and late-onset breast cancer.

Mandusic V, Dimitrijevic B, Nikolic-Vukosavljevic D, Neskovic-Konstantinovic Z, Kanjer K, Hamann U.

Cancer Lett. 2012 Aug 1;321(1):73-9. doi: 10.1016/j.canlet.2012.02.022. Epub 2012 Feb 24.

PMID:
22366496
11.

ERβ splice variant expression in four large cohorts of human breast cancer patient tumors.

Wimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M, Figueroa J, Rimm DL.

Breast Cancer Res Treat. 2014 Aug;146(3):657-67. doi: 10.1007/s10549-014-3050-3. Epub 2014 Jul 10.

PMID:
25007965
12.

The expression of estrogen receptors β2, 5 identifies and is associated with prognosis in non-small cell lung cancer.

Liu Z, Liao Y, Tang H, Chen G.

Endocrine. 2013 Oct;44(2):517-24. doi: 10.1007/s12020-013-9916-z. Epub 2013 Mar 10.

PMID:
23475473
13.

The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.

Zannoni GF, Monterossi G, De Stefano I, Gargini A, Salerno MG, Farulla I, Travaglia D, Vellone VG, Scambia G, Gallo D.

Hum Pathol. 2013 Jun;44(6):1047-54. doi: 10.1016/j.humpath.2012.09.007. Epub 2012 Dec 21.

PMID:
23266443
14.
15.

The potential role of estrogen receptor β2 in breast cancer.

Baek JM, Chae BJ, Song BJ, Jung SS.

Int J Surg. 2015 Feb;14:17-22. doi: 10.1016/j.ijsu.2014.10.007. Epub 2014 Nov 7.

16.

ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates.

Wong NA, Malcomson RD, Jodrell DI, Groome NP, Harrison DJ, Saunders PT.

J Pathol. 2005 Sep;207(1):53-60.

PMID:
15954165
17.

Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma.

Chakravarty D, Srinivasan R, Ghosh S, Gopalan S, Rajwanshi A, Majumdar S.

Int J Gynecol Cancer. 2007 Jul-Aug;17(4):905-13. Epub 2007 Feb 16.

PMID:
17309672
18.

Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3.

Dey P, Jonsson P, Hartman J, Williams C, Ström A, Gustafsson JÅ.

Mol Endocrinol. 2012 Dec;26(12):1991-2003. doi: 10.1210/me.2012.1227. Epub 2012 Oct 1.

19.

Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.

Chan KKL, Siu MKY, Jiang YX, Wang JJ, Wang Y, Leung THY, Liu SS, Cheung ANY, Ngan HYS.

BMC Cancer. 2017 Aug 31;17(1):606. doi: 10.1186/s12885-017-3601-1.

20.

Kindlin-2 inhibits serous epithelial ovarian cancer peritoneal dissemination and predicts patient outcomes.

Ren C, Du J, Xi C, Yu Y, Hu A, Zhan J, Guo H, Fang W, Liu C, Zhang H.

Biochem Biophys Res Commun. 2014 Mar 28;446(1):187-94. doi: 10.1016/j.bbrc.2014.02.087. Epub 2014 Feb 27.

PMID:
24583125

Supplemental Content

Support Center